Hospira Acquires Orchid's API Manufacturing and R&D Facilities - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Hospira Acquires Orchid's API Manufacturing and R&D Facilities

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 8

Hospira reported it has completed the acquisition of an API manufacturing facility and an associated R&D facility from Orchid Chemicals & Pharmaceuticals, an Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.

The acquisition enables Hospira to vertically integrate into the beta-lactam antibiotic APIs (penems and penicillins) and is also expected to improve Hospira's cost position in this therapeutic space. In addition, backward integration into these beta-lactam APIs will improve the company's security of supply.

The API manufacturing facility, located in Aurangabad, India has capabilities for manufacturing sterile APIs and employs approximately 665 employees including chemists, engineers, and technicians. The associated R&D facility is based in Chennai, India, and will be directed primarily to beta-lactam and other API developments with approximately 110 scientific personnel.

Post deal, Orchid retains its cephalosporin API business and facilities and certain non-antibiotic, non-sterile businesses, and facilities it owns. Orchid will continue to supply Hospira with cephalosporin APIs.

Source: Hospira


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here